Let's Connect

G6PD deficiency is the most common enzyme deficiency in humans, affecting over 400 million people worldwide. It's a genetic condition where red blood cells lack sufficient glucose-6-phosphate dehydrogenase enzyme, making them vulnerable to oxidative stress from certain medications, foods, and infections.

Currently, there is no cure for G6PD deficiency. Management focuses on avoiding triggers that can cause hemolytic episodes. However, emerging gene therapy approaches like CRISPR are being researched as potential future treatments. My research explores these possibilities.

I created G6PD.ai, an AI-powered tool that helps G6PD-deficient individuals check the safety of medications, foods, and chemicals. Simply describe what you want to check, and the AI will provide safety information based on medical literature. Always consult your healthcare provider for personalized advice.

Yes! I welcome collaborations from researchers, clinicians, and fellow patients. Whether you have computational biology expertise, clinical insights, or simply want to share your experience living with G6PD deficiency, please reach out via email. Together, we can accelerate progress toward better treatments.

G6PD deficiency provides partial protection against malaria, which is why it's more common in populations from malaria-endemic regions (Africa, Mediterranean, Middle East, Southeast Asia). This is an example of "balanced polymorphism" – the gene persists because carriers have a survival advantage in malaria-prone areas.